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TITLE OF CASE Do not include “a case report” 
 
Modified Valsalva Manoeuvre to treat recurrent supraventricular tachycardia: 
Description of the technique and its successful use in a patient with a previous 
near fatal complication of DC cardioversion  
SUMMARY Up to 150 words summarising the case presentation and outcome (this 
will be freely available online) 
Patients with attacks of re-entrant supraventricular tachycardia (SVT) frequently 
present to the emergency department (ED).  The Valsalva manoeuvre (VM) is the 
most effective and safe vagal manoeuvre and advocated as first line treatment in 
stable patients but has a relatively low cardioversion success rate. Improving its 
efficacy would reduce patients’ exposure to the side effects and complications of 
second line treatments and has other potential benefits. We describe a 
modification to the VM which is currently being studied and the case of a 23 year 
old patient who was successfully treated with this modified VM after a previous 
near fatal complication of DC Cardioversion. 
 
BACKGROUND Why you think this case is important – why did you write it up? 
This is the first description we can find of this particular modification to the Valsalva 
Manoeuvre (VM) and how it was successfully used in a patient whose re-entrant 
supraventricular tachycardia (SVT) was thought to be refractory to such vagal techniques. It 
suggests that employing a more effective VM might reduce the number of patients who go 
on to require unpleasant, more invasive and potentially dangerous treatments. It also 
specifically describes the modification technique that is currently undergoing national 
portfolio randomised controlled trial evaluation. 
 
 
 
CASE PRESENTATION Presenting features, medical/social/family history 
A 23 year old male presented to the ED with SVT. His heart rate was 106, blood pressure 
120/55 and he was alert but uncomfortable and complaining of palpitations.  He weighed 
140Kg and was un-starved.  
 
The patient was well known to the hospital with recurrent SVT, of slow rate, with attacks 
requiring hospital attendance on more than 30 occasions over 13 years. Previously, standard 
vagal manoeuvres had always been unsuccessful and intravenous adenosine avoided due to 
intolerable side effects and previous ineffectiveness. Intravenous verapamil had also been 
unsuccessful. Intravenous flecanide had occasionally worked but his SVT continued to recur 
despite regular oral flecanide and bisoprolol.  
 
He had undergone appropriate specialist investigation and review previously but had 
declined (with capacity) several offers of radio-frequency ablation therapy prior to this 
attendance. Latterly, the most effective emergency treatment had been DC cardioversion. He 
had undergone this on 12 previous attendances and there was an agreed multispecialty plan 
for its use.  
 
At his previous attendance, once more a failed standard Valsalva manoeuvre (VM) had been 
followed by attempted DC cardioversion. However, during the procedure, the synchronisation 
mode of the defibrillator had either malfunctioned or been inadvertently re-set. The 
consequent delivery of an unsynchronised shock resulted in ventricular fibrillation. 12 
minutes of advanced life support and 4 attempts at defibrillation was required before return 
of spontaneous circulation. He subsequently spent 24 hours in intensive care and 3 days in 
hospital before being discharged neurologically intact. 
 
 
 
 
 
 
 
 
INVESTIGATIONS If relevant  
His initial ECG, showed a re-entrant SVT, typical of previous attacks and like these had an 
unusually slow rate which was thought to be due to his bisoprolol and flecanide therapy. 
Copies of his pre- (figure 1) and post- (figure 2) cardioversion ECG are shown. 
 
 
 
DIFFERENTIAL DIAGNOSIS If relevant 
 
 
 
 
TREATMENT If relevant  
Given this previous complication, un-starved state and understandable anxiety about DC 
cardioversion, it was decided to attempt a VM using a modification for which a research 
proposal was being developed locally: 
 
Modified Valsalva Manoeuvre Technique:  This requires the patient to perform a standardised 
Valsalva strain (to 40mmHg, verified on a manometer) in a semi-recumbent position for 15 
seconds before being laid flat and their legs passively lifted to 45 degrees by staff 
immediately at the end of the strain to maximise venous return in the relaxation phase for a 
further 15 seconds. 
 
This was immediately successful with return of sinus rhythm during the leg lift and the 
patient was discharged with advice as how to perform this modified VM himself using a 10ml 
syringe (shown to equate to 40mmHg pressure when blown to just effect plunger 
movement[1]) with passive leg lift by a family member.  
 
 
OUTCOME AND FOLLOW-UP   
 
This modified VM has been added to the patient’s management plan. Over the 2 years since 
he was first successfully treated, the patient has only attended ED 4 further times with an 
SVT. He has been successfully treated with the modified VM on three of these occasions (the 
other being with iv flecanide without prior use of any VM). He reports he has successfully 
used this manoeuvre on numerous occasions at home as advised, negating the need to 
attend ED. 
 
 
DISCUSSION Include a very brief review of similar published cases  
 
Vagal manoeuvres such as the VM are recommended first line emergency treatments for SVT 
but often lack efficacy. Evidence for the optimum VM technique is limited[2] though 
electrophysiology laboratory studies suggest a strain of 40mmHg for 15 seconds leads to the 
greatest reflex bradycardia in healthy volunteers[3].  
 
Modifications to the VM have been described[4,5,6] and may affect its efficacy in the ED 
setting[7]. Venous return is increased due to the effects of gravity on blood in the lower limb 
veins and it is hypothesised that a passive leg lift during phase 3 of the Valsalva, performed 
immediately at the end of the strain period (phase 1&2), may lead to an exaggerated 
 
overshoot in blood pressure in phase 4. This may result in greater vagal stimulation to effect 
bradycardia and increase the chance of cardioversion. A passive leg lift is used as straining 
to actively lift legs may increase sympathetic tone during phase 3 and therefore be 
counterproductive. 
 
There is some evidence that a passive leg lift performed during a supine Valsalva leads to 
greater vagal tone in normal volunteers compared to a sitting or semi-recumbent 
Valsalva[8]. Although, in this study greater vagal tone was achieved with a plain supine 
Valsalva, the effect of passive leg lift and supine positioning at the end of a semi-recumbent 
strain phase (1&2), as used in our case, is unknown. A Valsalva strain performed semi-
recumbent may initially exaggerate reduced venous return and hence increase sympathetic 
stimulation during phase 1&2 which is suddenly reversed with the drop in intrathoracic 
pressure and increased venous return afforded by the supine position and passive leg lift in 
phase 3 used in the modified manoeuvre we describe. 
 
This is the first report we can find of the particular manoeuvre used in our patient to treat 
SVT and has not been previously studied in normal volunteers or patients. Our region is 
currently conducting a randomised trial of this modification compared to a standard VM in 
patients presenting to the ED with SVT[9],[10]. 
 
Second line treatments for SVT are efficacious but not without side effects and, as our case 
graphically illustrated, potentially serious, albeit rare complications. Although intravenous 
adenosine is highly effective, safe and favoured by ED physicians[11], many patients find it 
very unpleasant and frightening[12]. A more successful VM will reduce the need for patients 
to go onto receive these treatments and to have a more effective home treatment, saving 
them and ED staff time.  
 
We have described a case where the use of a modified VM successfully converted a patient’s 
SVT which had been thought to be refractory to vagal manoeuvres. They had previously 
suffered a severe complication of second line treatment which may have been avoided with 
use of this simple physical treatment which is currently being further evaluated in a 
controlled trial.   
 
 
 
LEARNING POINTS/TAKE HOME MESSAGES 3 to 5 bullet points – this is a required 
field 
 Vagal manoeuvres remain the first line treatment for patients presenting with stable 
SVT 
 The Valsalva Manoeuvre (VM) is the safest most effective vagal technique but is often 
ineffective in standard practice  
 Other treatments for SVT are not entirely without risk or discomfort 
 A postural modification to the VM might improve its efficacy and prevent the need for 
further emergency treatment 
 The modified VM technique described in this case report is now undergoing 
randomised controlled trial evaluation 
 
 
 
REFERENCES Vancouver style (Was the patient involved in a clinical trial? Please 
reference related articles) 
1. Smith G, Boyle M. The 10ml syringe is useful in generating the recommended 
standard of 40mmHg intrathoracic pressure for the Valsalva manoeuvre. Emerg 
Med Aust 2009;21:449-454 
 
2. Smith GD, Dyson K, Taylor D, et al. Effectiveness of the Valsalva Manoeuvre for 
reversion of supraventricular tachycardia. Cochrane Database of Systematic 
Reviews 2013, Issue 3. Art. No.: CD009502. DOI: 
10.1002/14651858.CD009502.pub2. 
 
3. Looga R. The Valsalva manoeuvre – cardiovascular effects and performance 
technique: a critical review. Respir Physiol Neurobiol 2005; 147: 39-49 
 
4. Chance JF, Warner JG, Elsawy T. Augmented Valsalva maneuver for 
supraventricaular tachycardia in the young. Ann Intern Med 1992; 116: 523 
 
5. Torren A. Modified Valsalva manoeuvre for paroxysmal supraventricular 
tachycardia [Letter]. Cardiovasc Drugs Ther 1997;  11: 91 
 
6. Mitchell ARJ. Augmented Valsalva manoeuvre in the management of 
supraventricular tachycardia. Br J Cardiol 1998; 5: 651-652 
 
7. Walker S, Cutting P. Impact of a modified Valsalva manoeuvre in the termination 
of paroxysmal supraventricular tachycardia. Emerg Med J 2010;27:287-291 
 
8. Wong LF, Taylor DM, Bailey M. Vagal response varies with Valsalva maneuver 
technique: A repeated-measures clinical trial in healthy subjects. Ann Emerg Med 
2004;43(4):477-482 
 
9. The REVERT Trial: Current Controlled Trials (ISRCTN67937027).  
 
10. Appelboam A, Reuben AD, Mann C. Randomised Evaluation of modified Valsalva 
Effectiveness in Re-entrant Tachycardias (REVERT) study.  BMJ Open 
2014;4:e004525 doi:10.1136/bmjopen-2013-004525 
 
11. Innes JA. Review article: Adenosine use in the emergency department. Emerg 
Med Australas 2008; 20(3): 209-215 
 
12. Patient testimonies: 
http://www.heartrhythmcharity.org.uk/www/218/0/Patient_stories/ 
 
 
 
 
FIGURE/VIDEO CAPTIONS figures should NOT be embedded in this document 
Figure 1. Pre-Valsalva ECG showing slow rate SVT 
Figure 2. Post-Modified Valsalva ECG confirming sinus rhythm 
 
 
 
PATIENT’S PERSPECTIVE Optional but encouraged 
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